acute myocardial infarction

Reperfusión en tiempos de coronavirus

Is Epinephrine Superior to Adenosine in No-REFLOW?

In patients with acute coronary syndrome, no-reflow prevalence is 32%. Different drugs—such as adenosine, verapamil, nitroprusside, or nicardipine— have been used for its intracoronary treatment, thus resulting in arterial hypotension. The aim of this randomized study was to determine the effectiveness of the use of intracoronary epinephrine vs. adenosine in normotensive patients. The primary endpoint<a href="https://solaci.org/en/2022/03/09/is-epinephrine-superior-to-adenosine-in-no-reflow/" title="Read more" >...</a>

The Most Relevant of 2021 In Coronary Disease

This last year, new data in coronary disease gave way to changes in practices and new hypotheses, when not simply further justified the already existing evidence.&nbsp; In this new editorial section, we share the most relevant of last year’s works to keep you up to speed on the main topics in the field. The Most<a href="https://solaci.org/en/2022/01/06/the-most-relevant-of-2021-in-coronary-disease/" title="Read more" >...</a>

The Most Read Articles of 2021: Pharmacology

A new year is coming to an end and at SOLACI we are going over the most read studies on our website, on a vital topic, pharmacology. Follow us to keep up to date. The Most Read Articles of 2021: Pharmacology 01- Swan Ganz Associated with Better Outcomes in Cardiogenic Shock: Is It Back? The&nbsp;Swan<a href="https://solaci.org/en/2021/12/24/the-most-read-articles-of-2021-pharmacology/" title="Read more" >...</a>

TCT 2021 | FAME 3: Sorpresas en un estudio largamente esperado

TCT 2021 | FAME 3: Surprises in a Long-Awaited Study

Angioplasty could not reach non-inferiority to surgery to treat patients with three-vessel lesions. In this head-to-head study of both revascularization strategies in patients with three-vessel coronary disease, fractional flow reserve (FFR)-guided angioplasty could not reach the performance of myocardial revascularization surgery in relation to a composite of adverse events. The FAME&nbsp;3 study was presented during<a href="https://solaci.org/en/2021/11/10/tct-2021-fame-3-surprises-in-a-long-awaited-study/" title="Read more" >...</a>

Los balones farmacológicos pasaron la prueba del tiempo en territorio femoropoplíteo

Drug-Eluting Balloons Find Their Niche

According to this large European registry, drug-eluting balloons (DEBs) are competing with drug-eluting stents (DES) to treat in-stent restenosis. Drug-eluting balloons seem to work equally well for the treatment of long-term in-stent restenosis compared with new stent implantation (for the thin-strut DES registry). If DEBs can compete with DES—adding to the advantage of avoiding a<a href="https://solaci.org/en/2021/10/13/drug-eluting-balloons-find-their-niche/" title="Read more" >...</a>

The most read scientific papers of September in interventional cardiology

01- ESC 2021 | Updated European Society of Cardiology Guidelines for the Management of Valvular Heart Disease Early intervention in asymptomatic valvular heart disease, age recommendations to decide between TAVR and surgery for aortic stenosis, and a push in favor of transcatheter repair in secondary mitral regurgitation are some of the new modifications to the&nbsp;European<a href="https://solaci.org/en/2021/10/01/the-most-read-scientific-papers-of-september-in-interventional-cardiology/" title="Read more" >...</a>

FLOWER-MI Sub-Studies Coming Out Generate More Questions about FFR

The FLOWER-MI (presented simultaneously at ACC 2021 and NEJM) hit FFR hard. Its outcomes showed that STEMI patients presenting other non-culprit lesions did not benefit from FFR guided revascularization vs PCI. As it happens with most large studies with unexpected results in the general population, the sub-studies that follow select better samples and, as a<a href="https://solaci.org/en/2021/09/08/flower-mi-sub-studies-coming-out-generate-more-questions-about-ffr/" title="Read more" >...</a>

ACC 2021 | Sacubitril/valsartan no es superior al ramipril luego de un IAM

ACC 2021 | Sacubitril/Valsartan not Superior to Ramipril after AMI

The combination sacubitril/valsartan following high-risk AMI&nbsp;did not reduce the risk of cardiac failure or cardiovascular risk in patients compared against ramipril. These data were provided by the PARADISE-MI presented today during the scientific sessions at ACC 2021. The combination sacubitril/valsartan had gathered prior evidence (basically from the PARADIGM-HF) for its superiority in terms of total<a href="https://solaci.org/en/2021/05/18/acc-2021-sacubitril-valsartan-not-superior-to-ramipril-after-ami/" title="Read more" >...</a>

Nueva y discrepante información sobre los vasos no culpables en el infarto

New Unexpected Data on Non-Culprit Vessels in MI

Patients with acute myocardial infarction presenting lesions in multiple vessels is not associated with reduced infarct size in non-culprit lesions, even when functionally significant.&nbsp; Animal models suggest brief periods of ischemia in non-infarct territories (non-culprit) might protect culprit territory thanks to remote ischemic preconditioning.&nbsp; This pre-conditioning, according to this perspective, would reduce reperfusion injury and<a href="https://solaci.org/en/2021/05/11/new-unexpected-data-on-non-culprit-vessels-in-mi/" title="Read more" >...</a>

Desafíos pendientes con el acceso radial

MATRIX: Impact of Crossover from Radial Access to Femoral Access

The new MATRIX trial, recently published in JACC Interv., shows that an access-site crossover from radial to femoral access in patients with acute coronary syndrome cancels out the benefit provided by radial access as regards bleeding.&nbsp; However, there are no signs of comparative damage between successfully conducted radial or femoral access as a first attempt.&nbsp;<a href="https://solaci.org/en/2021/03/17/matrix-impact-of-crossover-from-radial-access-to-femoral-access/" title="Read more" >...</a>

Top